BACKGROUND: Use of drug-eluting stents (DES) has reduced in-stent restenosis after percutaneous coronary intervention (PCI); however, DES are associated with late stent thrombosis. There is no accurate way to predict in-stent restenosis, although risk factors for atherosclerosis overlap those for in-stent restenosis. Therefore, we evaluated atherosclerosis candidate genes for association with in-stent restenosis. METHODS: We identified 46 consecutive cases that had undergone PCI with bare-metal stents who subsequently developed symptomatic in-stent restenosis of the target lesion (>/=75% luminal narrowing) within 6 months. Forty-six age-, race-, vessel-diameter- and sex-matched controls without in-stent restenosis after PCI with bare-metal stent were also identified. Single-nucleotide polymorphisms (SNPs, N=82) from 39 candidate atherosclerosis genes were genotyped. Multivariable logistic regression models were used to test for association. RESULTS: Five SNPs were associated with in-stent restenosis. Three ALOX5AP SNPs were most strongly associated, two with increased risk (OR 3.74, p=0.01; OR 3.46, p=0.02), and the third with decreased risk of in-stent restenosis (OR 0.09, p=0.004). Two ALOX5AP haplotypes were associated with in-stent restenosis (HapB: OR 3.13, p=0.03); and a haplotype similar to HapA: OR 0.14, p=0.0009). CONCLUSIONS: ALOX5AP, a gene within the inflammatory leukotriene pathway linked to and associated with coronary atherosclerosis, is also associated with in-stent restenosis. Genotyping these variants may help identify those at risk for in-stent restenosis who would benefit most from use of DES.
BACKGROUND: Use of drug-eluting stents (DES) has reduced in-stent restenosis after percutaneous coronary intervention (PCI); however, DES are associated with late stent thrombosis. There is no accurate way to predict in-stent restenosis, although risk factors for atherosclerosis overlap those for in-stent restenosis. Therefore, we evaluated atherosclerosis candidate genes for association with in-stent restenosis. METHODS: We identified 46 consecutive cases that had undergone PCI with bare-metal stents who subsequently developed symptomatic in-stent restenosis of the target lesion (>/=75% luminal narrowing) within 6 months. Forty-six age-, race-, vessel-diameter- and sex-matched controls without in-stent restenosis after PCI with bare-metal stent were also identified. Single-nucleotide polymorphisms (SNPs, N=82) from 39 candidate atherosclerosis genes were genotyped. Multivariable logistic regression models were used to test for association. RESULTS: Five SNPs were associated with in-stent restenosis. Three ALOX5AP SNPs were most strongly associated, two with increased risk (OR 3.74, p=0.01; OR 3.46, p=0.02), and the third with decreased risk of in-stent restenosis (OR 0.09, p=0.004). Two ALOX5AP haplotypes were associated with in-stent restenosis (HapB: OR 3.13, p=0.03); and a haplotype similar to HapA: OR 0.14, p=0.0009). CONCLUSIONS:ALOX5AP, a gene within the inflammatory leukotriene pathway linked to and associated with coronary atherosclerosis, is also associated with in-stent restenosis. Genotyping these variants may help identify those at risk for in-stent restenosis who would benefit most from use of DES.
Authors: L J Feldman; M Mazighi; A Scheuble; J F Deux; E De Benedetti; C Badier-Commander; E Brambilla; D Henin; P G Steg; M P Jacob Journal: Circulation Date: 2001-06-26 Impact factor: 29.690
Authors: T M DeChiara; R B Kimble; W T Poueymirou; J Rojas; P Masiakowski; D M Valenzuela; G D Yancopoulos Journal: Nat Genet Date: 2000-03 Impact factor: 38.330
Authors: Mathias Rauchhaus; Michael Gross; Susanne Schulz; Darrel P Francis; Petra Greiser; Antje Norwig; Lorenz Weidhase; Andrew J S Coats; Rainer Dietz; Stefan D Anker; Christiane Gläser Journal: Int J Cardiol Date: 2002-06 Impact factor: 4.164
Authors: A Kastrati; W Koch; P B Berger; J Mehilli; K Stephenson; F J Neumann; N von Beckerath; C Böttiger; G W Duff; A Schömig Journal: J Am Coll Cardiol Date: 2000-12 Impact factor: 24.094
Authors: Gregg W Stone; Jeffrey W Moses; Stephen G Ellis; Joachim Schofer; Keith D Dawkins; Marie-Claude Morice; Antonio Colombo; Erick Schampaert; Eberhard Grube; Ajay J Kirtane; Donald E Cutlip; Martin Fahy; Stuart J Pocock; Roxana Mehran; Martin B Leon Journal: N Engl J Med Date: 2007-02-12 Impact factor: 91.245
Authors: W Koch; C Böttiger; J Mehilli; N von Beckerath; F J Neumann; A Schömig; A Kastrati Journal: Am J Cardiol Date: 2001-11-15 Impact factor: 2.778
Authors: Marie-Claude Morice; Patrick W Serruys; J Eduardo Sousa; Jean Fajadet; Ernesto Ban Hayashi; Marco Perin; Antonio Colombo; G Schuler; Paul Barragan; Giulio Guagliumi; Ferenc Molnàr; Robert Falotico Journal: N Engl J Med Date: 2002-06-06 Impact factor: 91.245
Authors: William E Kraus; Christopher B Granger; Michael H Sketch; Mark P Donahue; Geoffrey S Ginsburg; Elizabeth R Hauser; Carol Haynes; L Kristin Newby; Melissa Hurdle; Z Elaine Dowdy; Svati H Shah Journal: J Cardiovasc Transl Res Date: 2015-08-14 Impact factor: 4.132
Authors: Charles B Stephensen; Patrice Armstrong; John W Newman; Theresa L Pedersen; Jillian Legault; Gertrud U Schuster; Darshan Kelley; Susanna Vikman; Jaana Hartiala; Rami Nassir; Michael F Seldin; Hooman Allayee Journal: J Lipid Res Date: 2011-02-04 Impact factor: 5.922
Authors: David R Crosslin; Svati H Shah; Sarah C Nelson; Carol S Haynes; Jessica J Connelly; Shera Gadson; Pascal J Goldschmidt-Clermont; Jeffery M Vance; Jason Rose; Chris B Granger; David Seo; Simon G Gregory; William E Kraus; Elizabeth R Hauser Journal: Hum Genet Date: 2009-01-08 Impact factor: 4.132
Authors: Jaana Hartiala; Dalin Li; David V Conti; Susanna Vikman; Yesha Patel; W H Wilson Tang; Marie-Louise Brennan; John W Newman; Charles B Stephensen; Patrice Armstrong; Stanley L Hazen; Hooman Allayee Journal: Hum Genet Date: 2011-02-04 Impact factor: 4.132